GlassScriptPhysician profile
Denise Milton
NPI 1144385030
$6,035.53
in general payments reported to CMS, 2019-2025
11 companies · $925 in 2025
The $925 reported for 2025 was more than what 93% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $709 · 2022: $1,194 · 2023: $1,430 · 2024: $1,777 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,132.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,394.41 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,177.92 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,068.32 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $747.09 | 2022-2024 | Lybalvi, Aristada, Aristada Initio |
| Axsome Therapeutics, INC. | $610.81 | 2024-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $316.44 | 2022-2024 | Uzedy, Austedo Xr |
| Jazz Pharmaceuticals INC. | $234.68 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.87 | 2024-2025 | Trintellix |
| Corium, LLC | $122.06 | 2023 | Azstarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $120.00 | 2022 | |
| Neurocrine Biosciences, INC. | $111.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Milton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.